Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

208 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
BU
Guardant Health - Royal Marsden And Guardant Health Partnership Provides State-of-the-art Blood Test To Benefit Lung Cancer Patients In Expanded NHS Study
AQ
Transcript : Guardant Health, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Guardant Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
BU
Guardant Health Announces Preliminary Fourth Quarterand Full Year 2023 Results
AQ
Transcript : Guardant Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2023 Results
BU
Guardant Health Appoints Terilyn Juarez Monroe as Chief People Officer
BU
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
BU
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
BU
Guardant Health to Appeal Federal District Court Verdict
BU
Transcript : Guardant Health, Inc., Q3 2023 Earnings Call, Nov 06, 2023
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
BU
Transcript : Guardant Health, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 11:20 AM
GUARDANT HEALTH RECEIVES COVERAGE FOR GUARDANT REVEAL FROM GEISINGER HEALTH PLAN
AQ
Transcript : Guardant Health, Inc. - Analyst/Investor Day
GUARDANT HEALTH RECEIVES REGULATORY APPROVAL IN JAPAN FOR GUARDANT360 CDX AS COMPANION DIAGNOSTIC TO ENHERTU FOR TREATMENT OF NON-SMALL CELL LUNG CANCER PATIENTS WITH HER2 MUTATIONS
AQ
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
BU
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
BU
Transcript : Guardant Health, Inc., Q2 2023 Earnings Call, Aug 03, 2023
Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance
BU
Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana
BU
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
BU
Transcript : Guardant Health, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-12-2023 04:00 PM
Transcript : Guardant Health, Inc. Presents at The 43rd Annual William Blair Growth Stock Conference, Jun-06-2023 04:40 PM
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
BU
Guardant Health Secures Coverage from Major US Commercial Health Insurers for Guardant360 Blood Test for Comprehensive Genomic Profiling
AQ
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
BU
Guardant Health Releases Inaugural ESG Report
BU
Transcript : Guardant Health, Inc. Presents at Bank of America Securities 2023 Healthcare Conference, May-10-2023 02:20 PM
Transcript : Guardant Health, Inc., Q1 2023 Earnings Call, May 09, 2023
Guardant Health Reports First Quarter 2023 Financial Results
BU
Guardant Health Announces Additions to Leadership Team
BU
Guardant Health and Parker Institute for Cancer Immunotherapy launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
AQ
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
BU
Guardant Health Receives Medicare Coverage for Guardant360 Response to Monitor Cancer Patient Response to Immunotherapy
AQ
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
BU
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
BU
Transcript : Guardant Health, Inc. Presents at Cowen 43rd Annual Healthcare Conference, Mar-08-2023 10:30 AM
Musa Tariq Joins Guardant Health Board of Directors
BU
Transcript : Guardant Health, Inc., Q4 2022 Earnings Call, Feb 23, 2023
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
BU
Guardant Health receives coverage from UnitedHealthcare for Guardant360 CDx blood test as companion diagnostic in advanced lung and breast cancer
AQ
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
BU
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360 CDx and Guardant360 TissueNext as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
AQ
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
BU
Guardant Health introduces Guardant Galaxy suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
AQ
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
BU
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
BU
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal blood test to help guide treatment decisions in colorectal cancer
AQ
No results for this search
  1. Stock Market
  2. Advanced search
  3. Helmy Eltoukhy
  4. News
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW